The miR-196a SNP Rs11614913 but not the miR-499 rs37464444 SNP is a Risk Factor for Non-small Cell Lung Cancer in an Iranian Population.
Lung Cancer
NSCLC
miR-499
rs11614913, miR196a
rs3746444
Journal
Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
01
04
2021
accepted:
13
09
2021
entrez:
19
10
2022
pubmed:
20
10
2022
medline:
20
10
2022
Statut:
ppublish
Résumé
Globally, lung cancer represents a major cause of cancer-related deaths. The regulation of gene expression is modulated by small noncoding RNAs called miRNAs that can act as both tumor suppressors and oncogenes. The maturation, expression and binding to target mRNAs is affected by single nucleotide polymorphisms (SNPs) in miRNA genomic regions thereby contributing to cancer susceptibility. SNPs Rs11614913 in miR196a and Rs3746444 in miR-499 are implicated in the development of cancers such as non-small cell lung cancer (NSCLC) in non-Arabic subjects. A small cohort of 204 participants including 104 lung cancer patients and 100 non-cancer controls subjects were enrolled into the study. The allele frequencies were determined by Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) and their correlation with lung cancer risk was determined. The miR-196a rs11614913 polymorphism increased the risk of NSCLC (CC vs. TT+TC: OR= 2.26, 95%CI= 1.28 - 3.98, P= 0.0046) in a dominant genetic model. No statistically significant association was found between the miR-499 rs37464444 polymorphism and NSCLC. The rs11614913 polymorphism in miR-196a, but not the miR-499 rs37464444 polymorphism, increased the risk of NSCLC. Further studies with larger sample sizes in correlation with functional outcomes at the cellular level should be undertaken.
Sections du résumé
Background
UNASSIGNED
Globally, lung cancer represents a major cause of cancer-related deaths. The regulation of gene expression is modulated by small noncoding RNAs called miRNAs that can act as both tumor suppressors and oncogenes. The maturation, expression and binding to target mRNAs is affected by single nucleotide polymorphisms (SNPs) in miRNA genomic regions thereby contributing to cancer susceptibility. SNPs Rs11614913 in miR196a and Rs3746444 in miR-499 are implicated in the development of cancers such as non-small cell lung cancer (NSCLC) in non-Arabic subjects.
Materials and Methods
UNASSIGNED
A small cohort of 204 participants including 104 lung cancer patients and 100 non-cancer controls subjects were enrolled into the study. The allele frequencies were determined by Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) and their correlation with lung cancer risk was determined.
Results
UNASSIGNED
The miR-196a rs11614913 polymorphism increased the risk of NSCLC (CC vs. TT+TC: OR= 2.26, 95%CI= 1.28 - 3.98, P= 0.0046) in a dominant genetic model. No statistically significant association was found between the miR-499 rs37464444 polymorphism and NSCLC.
Conclusion
UNASSIGNED
The rs11614913 polymorphism in miR-196a, but not the miR-499 rs37464444 polymorphism, increased the risk of NSCLC. Further studies with larger sample sizes in correlation with functional outcomes at the cellular level should be undertaken.
Types de publication
Journal Article
Langues
eng
Pagination
15-23Informations de copyright
Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease.
Références
Front Physiol. 2018 Jun 12;9:737
pubmed: 29946268
Mol Biol Rep. 2012 Dec;39(12):10433-8
pubmed: 23053947
J Thorac Oncol. 2013 Jun;8(6):703-10
pubmed: 23470291
Asian Pac J Cancer Prev. 2014;15(2):1047-55
pubmed: 24568449
Front Oncol. 2021 Nov 01;11:715677
pubmed: 34790566
Mol Carcinog. 2012 Oct;51 Suppl 1:E65-73
pubmed: 22161766
Genet Mol Res. 2016 Apr 28;15(2):
pubmed: 27173281
Clin Biochem. 2011 Jul;44(10-11):813-6
pubmed: 21565178
PLoS One. 2013 Jun 04;8(6):e65123
pubmed: 23750236
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1183-7
pubmed: 19293314
Epigenetics Chromatin. 2015 Dec 30;8:57
pubmed: 26719772
BMC Pulm Med. 2017 Apr 21;17(1):68
pubmed: 28431548
Eur J Pharmacol. 2016 Nov 15;791:395-404
pubmed: 27634639
Oncotarget. 2016 Jul 5;7(27):41715-41724
pubmed: 27232940
PLoS One. 2013 Sep 09;8(9):e70656
pubmed: 24039706
PLoS One. 2013 Apr 12;8(4):e61047
pubmed: 23593385
World J Gastroenterol. 2012 Jun 14;18(22):2827-31
pubmed: 22719192
PLoS Genet. 2018 Dec 17;14(12):e1007837
pubmed: 30557297
J Prev Med Public Health. 2011 May;44(3):125-30
pubmed: 21617338
Biosci Rep. 2021 Feb 26;41(2):
pubmed: 33554246
ScientificWorldJournal. 2013;2013:675851
pubmed: 23431257
Nat Rev Dis Primers. 2015 May 21;1:15009
pubmed: 27188576
BMC Med Genet. 2012 Dec 10;13:119
pubmed: 23228090
Tumour Biol. 2014 Mar;35(3):2351-8
pubmed: 24258110
Exp Mol Pathol. 2015 Aug;99(1):145-50
pubmed: 26112096
Clin Cancer Res. 2010 Jul 15;16(14):3713-20
pubmed: 20501619
Hum Immunol. 2013 Sep;74(9):1199-205
pubmed: 23792053
Onco Targets Ther. 2018 Mar 01;11:1121-1139
pubmed: 29535537
Clin Chem Lab Med. 2011 Sep 09;49(12):2073-80
pubmed: 21902575
Hum Mutat. 2010 Jan;31(1):E1052-7
pubmed: 19847796
Clin Chest Med. 2002 Mar;23(1):65-81, viii
pubmed: 11901921
PLoS One. 2013 Nov 20;8(11):e79584
pubmed: 24278149
J Natl Cancer Inst. 2018 Aug 1;110(8):795-796
pubmed: 29518204
Can Respir J. 2020 Nov 20;2020:8179415
pubmed: 33294082
BMC Med Genet. 2014 Nov 30;15:126
pubmed: 25433484
J Clin Invest. 2008 Jul;118(7):2600-8
pubmed: 18521189
Tumour Biol. 2014 Nov;35(11):10815-24
pubmed: 25077922
Gene. 2012 Oct 15;508(1):9-14
pubmed: 22903035
Oncotarget. 2017 Aug 10;8(41):70890-70898
pubmed: 29050330
J Viral Hepat. 2011 Jul;18(7):e399-407
pubmed: 21692953
J Adv Res. 2016 May;7(3):491-8
pubmed: 27222754
J Thorac Cardiovasc Surg. 2012 Oct;144(4):794-807
pubmed: 22818121
Gene. 2012 Nov 10;509(2):267-72
pubmed: 22922391
PLoS One. 2012;7(9):e45042
pubmed: 22970328